Emergent BioSolutions Inc. (LON: 0IGA)
London
· Delayed Price · Currency is GBP · Price in USD
11.28
+0.28 (2.55%)
At close: Jan 31, 2025
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $293.80M USD in the quarter ending September 30, 2024, with 8.61% growth. This brings the company's revenue in the last twelve months to $1.13B, up 2.05% year-over-year. In the year 2023, Emergent BioSolutions had annual revenue of $1.05B, down -6.10%.
Revenue (ttm)
$1.13B
Revenue Growth
+2.05%
P/S Ratio
n/a
Revenue / Employee
$703.44K
Employees
1,600
Market Cap
490.41M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Emergent BioSolutions News
- 17 days ago - Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) - GlobeNewsWire
- 19 days ago - Hikma Pharmaceuticals Partners with Emergent BioSolutions for KLOXXADO® Nasal Spray Distribution - GuruFocus
- 19 days ago - Emergent BioSolutions: Stock Is A Likely Winner In 2025 - Seeking Alpha
- 19 days ago - Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - Benzinga
- 19 days ago - Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals - GlobeNewsWire
- 20 days ago - Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola - GlobeNewsWire
- 25 days ago - Emergent BioSolutions exercises $20M option to supply DoD with BioThrax - Seeking Alpha
- 25 days ago - Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - GlobeNewsWire